Study of BEST1 Vitelliform Macular Dystrophy

Launched by COLUMBIA UNIVERSITY · Mar 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Best Vitelliform Macular Dystrophy (VMD), which affects vision and is caused by changes in a specific gene known as BEST1. The main goal of the study is to understand how this condition progresses over time in people who have been diagnosed with it. By gathering this information, researchers hope to find better ways to measure the effects of new treatments and identify suitable candidates for future clinical trials.

To participate in this study, you need to be diagnosed with BEST1-associated VMD by a qualified eye specialist and be willing to attend follow-up appointments over three years. Participants of all ages and genders can join, as long as they can give informed consent and do not have any other health issues that would prevent them from completing the necessary eye exams. This study is important because it will help shape future treatments for individuals affected by this eye disorder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide informed consent
• • Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years)
• Exclusion Criteria:
• • Systemic condition that prevents the participant from undergoing the exams